About Nicox

Who we are

Working with us HD

Creating a new international ophthalmic company

Nicox is a new international ophthalmic company, aiming to build a diversified portfolio of therapeutic products addressing the needs of eyecare practitioners and patients around the world.

We have already successfully completed 4 acquisitions in the ophthalmic area and we continue to actively seek and evaluate commercial and late-stage ophthalmic products as well as potential acquisitions of local ophthalmic companies in Europe’s largest markets.

Our global growth strategy is focused on outstanding international collaborations and on our proprietary nitric oxide-donating research platform.

A growing commercial portfolio

Our commercial portfolio currently includes the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. We also market a number of other ophthalmic products through our subsidiaries in Italy and in France, following the acquisitions of EuPharmed in December 2013 and of Doliage in September 2014, respectively.

We have a direct commercial presence in the five largest European markets (Germany, France, the United Kingdom, Italy and Spain), as well as partnerships with local distributors in a number of key international markets. We also intend to commercialize our future therapeutic products directly in the United States.

An innovative therapeutic pipeline

Latanoprostene bunod, in phase 3 for glaucoma

The Company’s pipeline includes latanoprostene bunod, a novel drug-candidate based on Nicox’s proprietary nitric oxide (NO)-donating research platform, developed by Bausch + Lomb for the potential treatment of glaucoma and ocular hypertension. Following positive phase 3 results, Bausch + Lomb expects that this product could be launched in the US mid-2016, pending regulatory approval.

AC-170, in phase 3 for allergic conjunctivitis

AC-170 is the most advanced compound of Aciex Therapeutics, Inc., which was acquired by Nicox in October 2014. AC-170 is a novel formulation of cetirizine being developed for topical application in the eye for the first time for the treatment of allergic conjunctivitis. This product could be launched in the US in 2016, pending regulatory approval.

Please check our pipeline to see our main R&D projects in the ophthalmic field.

Nicox across the globe

Nicox is headquartered in Sophia Antipolis (Nice area, France) and is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX).

Nicox has a direct commercial infrastructure in Germany (Berlin), France (Sophia Antipolis and Suresnes, Paris area), the United Kingdom (Guildford), Italy (Bresso, Milan area) and Spain (Madrid). 

Nicox also has a North American team based in Fort Worth (Texas, United States) and research capabilities in Bresso (Milan area, Italy).

Nicox employs around 125 people worldwide.